{"id":49607,"date":"2022-10-13T18:01:59","date_gmt":"2022-10-13T16:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-depression-treatment-therapy-market-research-and-forecast-report-2022-2028-featuring-key-players-eli-lilly-and-co-johnson-johnson-pfizer-merck-h-lundbeck-f-hoffmann-la-roche-res\/"},"modified":"2022-10-13T18:01:59","modified_gmt":"2022-10-13T16:01:59","slug":"global-depression-treatment-therapy-market-research-and-forecast-report-2022-2028-featuring-key-players-eli-lilly-and-co-johnson-johnson-pfizer-merck-h-lundbeck-f-hoffmann-la-roche-res","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-depression-treatment-therapy-market-research-and-forecast-report-2022-2028-featuring-key-players-eli-lilly-and-co-johnson-johnson-pfizer-merck-h-lundbeck-f-hoffmann-la-roche-res\/","title":{"rendered":"Global Depression Treatment Therapy Market Research and Forecast Report 2022-2028 Featuring Key Players – Eli Lilly and Co., Johnson & Johnson, Pfizer, Merck, H. Lundbeck, & F. Hoffmann-La Roche – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Depression Treatment Therapy Market Research and Forecast, 2022-2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global depression treatment market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period of 2020-2027.\n<\/p>\n

\nDepression treatments are the type of prescription given to alleviate the symptoms of anxiety disorders, mild chronic depression, and Major Depressive Disorder (MDD). The rising prevalence of depression among the global population is the major factor driving the growth of the depression treatment market.\n<\/p>\n

\nBesides, the increasing awareness about mental illness, and the growing geriatric population with a higher rate of depression, is another factor accelerating the market growth. According to the report of the World Health Organization (WHO) published in January 2020, there are around 800,000 suicide-related mortalities every year, and 264 million people of all ages suffer from depression globally.\n<\/p>\n

\nMoreover, depression is the second leading cause of suicide in the young generation which is expected to increase due to change in lifestyle and increasing workload. The presence of depression disorder cases is higher in the US. According to the estimates of Anxiety and Depression Foundation facts and statistics, 6.8 million adults, or 3.1% of the US population have been affected by a generalized anxiety disorder.\n<\/p>\n

\nIn line with this, 6 million adults, or 2.7% of the US population are affected by panic disorder. Other factors such as chronic medical conditions, crimes such as sexual abuse, femicide along other behavioral issues may further lead to depression, which in turn, creates demand for depression treatment drugs.\n<\/p>\n

\nSegmental Outlook<\/strong>\n<\/p>\n

\nThe global depression treatment market is segmented on the basis of drug type into selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and others.\n<\/p>\n

\nSelective Serotonin Reuptake Inhibitors (SSRIs) in Drug Type Segment Hold Significant Share<\/strong>\n<\/p>\n

\nThe Selective Serotonin reuptake inhibitors (SSRI) segment is anticipated to grow at a significant pace during the forecast period. The SSRI is a type of drug used to treat mental illnesses such as depression and anxiety disorder by elevating the extracellular levels of serotonin.\n<\/p>\n

\nSelective serotonin reuptake inhibitors are widely used across the globe as they are highly effective in the treatment of depression. These are the most commonly prescribed antidepressant drugs, as it possesses maximum benefits with fewer side effects as compared to other drugs. Similar to other antidepressants, certain SSRIs are prescribed as a treatment for chronic pain conditions.\n<\/p>\n

\nRegional Outlook<\/strong>\n<\/p>\n

\nThe global depression treatment market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.\n<\/p>\n

\nNorth America is estimated to be the leading region in the global depression treatment market and is expected to remain dominant during the forecast period. The factors contributing to the growth of this region include the presence of a large number of depression cases and the accessibility of antidepressants across the region.\n<\/p>\n

\nIn addition, the government policies regarding drug launches and generic drug production are the major factors driving the growth of the depression treatment market. The Asia-Pacific is estimated to be the fastest-growing region in the depression treatment market during the forecast period (2021-2027).\n<\/p>\n

\nAsia-Pacific is projected to have considerable growth in the global depression treatment market.<\/strong>\n<\/p>\n

\nAsia-Pacific is projected to be the fastest-growing market during the forecast period. The factor contributing to the growth of the depression treatment market in this region includes the rising prevalence of psychiatric disorders. Besides, the development of new therapies and devices to reduce the depression rate by investing high amounts through key market players are the key factors for the market growth. Moreover, the production of new antidepressant drugs in emerging countries such as China, India, Japan, and others is anticipated to drive the depression treatment market in the region.\n<\/p>\n

\nMarket Players Outlook<\/strong>\n<\/p>\n

\nSome of the key players of the depression market include Eli Lilly and Co., Johnson & Johnson, Pfizer, Inc., Merck & Co., Inc., H. Lundbeck A\/S., F. Hoffmann-La Roche Ltd, and others. In order to gain a strong position in the market, these players adopt various marketing strategies such as mergers & acquisitions, R&D, product launch, and geographical expansion so on.\n<\/p>\n

\nFor instance, in August 2019, Lupin, a pharmaceutical company had launched an antidepressant drug Fluoxetine Tablets USP, 10 mg and 20 mg. The company had received the US FDA approval for Prozac which is indicated for the treatment of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder.\n<\/p>\n

\nCompanies Mentioned<\/strong>\n<\/p>\n